Enovis (ENOV) Liabilities from Discontinued Operations (2016 - 2025)
Enovis' (ENOV) quarterly Liabilities from Discontinued Operations came in at $1.4 million in Q4 2025, down 99.78% quarter-over-quarter from $635.3 million in Q4 2021.
Powered by 
Analysis
Enovis (ENOV) Liabilities from Discontinued Operations (2016 - 2025) Analysis & Trends
Enovis (ENOV) has reported Liabilities from Discontinued Operations for 6 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $1.4 million in Q4 2025; TTM through Oct 2025 was $1.4 million, a N/A change from a year earlier, with the FY2021 full-year figure at $635.3 million, changed N/A from the prior year.
- Liabilities from Discontinued Operations was $1.4 million for Q4 2025 at Enovis, down from $635.3 million in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at $635.3 million in Q4 2021 and troughed at $1.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.40 Bn | 175.80 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.77 Bn | 122.55 Bn | 1.96 Bn |
| 3 | Medtronic | 117.21 Bn | 108.39 Bn | 6.34 Bn |
| 4 | Stryker | 105.12 Bn | 101.64 Bn | 4.50 Bn |
| 5 | Boston Scientific | 64.52 Bn | 63.98 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.95 Bn | 45.69 Bn | 1.35 Bn |
| 7 | Alcon | 33.09 Bn | 31.63 Bn | 1.68 Bn |
| 8 | Dexcom | 32.17 Bn | 30.23 Bn | 830.00 Mn |
| 9 | Steris | 20.75 Bn | 20.27 Bn | 684.20 Mn |
| 10 | Enovis | 1.08 Bn | 1.07 Bn | 359.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Oct 3, 2025 | 1.43 Mn |
| Dec 31, 2021 | 635.28 Mn |
| Sep 27, 2019 | 651.72 Mn |
| Jun 28, 2019 | 694.38 Mn |
| Dec 31, 2018 | 707.64 Mn |
| Sep 29, 2017 | 272.41 Mn |
| Dec 31, 2016 | 165.97 Mn |